WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV, ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the Danish Health and Medicines Authority granted marketing authorization to ILUVIEN® for the

WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that ILUVIEN® has been has granted marketing authorization in Norway for the treatment of vision

WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV)(ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the regulatory process for marketing authorizations in Belgium , the Czech Republic , Denmark ,

WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the Italian Medicines Agency (Agenzia Italiana del Farmaco) has granted marketing authorization to

Now Plans to Seek US approval of Medidur for Posterior Uveitis Based on One Phase III Trial WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced financial

WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release products for treating eye diseases, today announced that the Company presented the first peer-reviewed preclinical data demonstrating the use of pSivida's Tethadur™

WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that its financial results for the third quarter of fiscal year 2014 will be released after the market

WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that its licensee Alimera Sciences has signed an exclusive agreement with Specialised Therapeutics

WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release products for treating eye diseases, today announced that pSivida has been selected for the Ophthalmic Companies Showcase at The Ophthalmology Innovation Summit (OIS), April

WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the U.S. Food and Drug Administration (FDA) has established a Prescription Drug User Fee Act (PDUFA)

WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release products for treating eye diseases, today announced that pSivida's president and chief executive officer, Dr. Paul Ashton , will discuss pSivida's Tethadur™ technology

WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the New Drug Application for ILUVIEN for the treatment of chronic Diabetic Macular Edema has been

WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV ) (ASX:PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, announced today that RA Capital has entered into a securities purchase agreement with the Company to invest

WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the Scottish Medicines Consortium (SMC) has accepted ILUVIEN® for use within the National Health

WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced financial results for its second quarter ended December 31, 2013 .

WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV)(ASX:PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that Dr. Paul Ashton , President and CEO, will present at the 16 th Annual BioCEO & Investor Conference ,

WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV)(ASX:PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that Dr. Paul Ashton , President and CEO, will present at the 16 th Annual BioCEO & Investor Conference ,

WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that its financial results for the second quarter of fiscal year 2014 will be released after the market

First NHS patient treated on January 10, 2014 WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that its licensee Alimera Sciences has shipped initial

WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that its licensee Alimera Sciences has entered into labeling discussions with the U.S.